Case-control study shows that neonatal pneumococcal meningitis cannot be distinguished from group B Streptococcus...

Area of Science:

• Neonatal infectious diseases
• Bacterial meningitis epidemiology
• Vaccine impact assessment

Background:

• Streptococcus pneumoniae (S. pneumoniae) is an identified cause of neonatal bacterial meningitis.
• Group B Streptococcus (GBS) is a leading cause of neonatal meningitis.
• Understanding the distinct features of S. pneumoniae meningitis is crucial for diagnosis and management.

Purpose of the Study:

• To describe the demographic, clinical, and biological features of neonatal S. pneumoniae meningitis.
• To compare S. pneumoniae meningitis with GBS meningitis in neonates.
• To evaluate the impact of the 13-valent pneumococcal conjugate vaccine (PCV13) on S. pneumoniae serotypes.

Main Methods:

• A case-control study design was employed.
• Neonates (1-28 days) with S. pneumoniae or GBS meningitis were compared.
• S. pneumoniae cases were matched to four GBS controls by age group and study year.

Main Results:

• From 2001-2013, S. pneumoniae accounted for 2.2% of 831 neonatal meningitis cases in France.
• Neonatal S. pneumoniae and GBS meningitis showed no significant differences in demographic, clinical, or biological characteristics.
• A decrease in PCV13 serotypes was observed post-vaccine implementation, with prevalence dropping from 88.9% to 20.0%.

Conclusions:

• Neonatal meningitis due to S. pneumoniae is clinically and biologically indistinguishable from GBS meningitis.
• The 13-valent pneumococcal conjugate vaccine (PCV13) implementation showed a potential herd effect, indicated by reduced vaccine serotype prevalence.